Tetra Bio-Pharma (TSXV:TBP) announced a non-binding term sheet with Altus Formulation for a joint venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications.

As quoted in the press release:

Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition. These include Intellitab abuse deterrent technology, Flexitab breakable sustained release tablet technology and SmartCelle nano-technology. SmartCelle’s ability to enhance the solubility of our THC and CBD products permits increased oral absorption and enables parenteral delivery. All platforms are protected by patents in force globally.

The Proposed Joint-Venture will provide Tetra Bio-Pharma with:

  • Increased intellectual property protection for products developed under the joint venture;
  • Access to abuse deterrent technology to minimize non-medical use of cannabinoids;
  • An enhanced development pipeline addressing new therapeutic areas;
  • Opportunities for disease-appropriate delivery including intranasal and intravenous delivery; and
  • Increased oral drug absorption with immediate and extended release products.

Click here to read the full press release.

Source: globenewswire.com

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less